Glycan dysregulation have been identified in a number of neurodegenerative disorders, and in AD the glycosylation profile of key disease regulators, such as APP, Tau, beta-secretase 1 (BACE1) and Nicastrin, have been shown to be altered. Here, BACE1 is linked to Alzheimer disease.